A fixed-dose combination (FDC) medication used primarily for the management of diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor (ARI) that reduces sorbitol accumulation in nerves, while Methylcobalamin is an active form of Vitamin B12 that supports nerve regeneration and myelin synthesis. This combination addresses both the metabolic and the nutritional aspects of nerve damage in diabetes.
Adult: One tablet of Epalrestat 150mg + Methylcobalamin 1500mcg, three times daily, taken orally before meals.
Note: Take tablet whole with water, preferably before meals. Do not crush or chew. Consistent timing of doses is important for Epalrestat. Treatment duration should be a minimum of 3 months for assessing efficacy.
The combination works via dual pathways. Epalrestat inhibits the enzyme aldose reductase in the polyol pathway, preventing the conversion of glucose to sorbitol. Accumulated sorbitol causes osmotic stress, oxidative damage, and reduced nerve conduction velocity. Methylcobalamin acts as a cofactor for methionine synthase, essential for myelin synthesis and neuronal repair. It also promotes nerve regeneration and may normalize aberrant nociceptive transmission.
Pregnancy: Category N (Not classified by US FDA). Animal studies with Epalrestat show teratogenicity. There is insufficient data in pregnant women. Use only if potential benefit justifies potential risk to the fetus. Methylcobalamin is generally safe.
Driving: Dizziness has been reported. Patients should be cautioned about driving or operating machinery if they experience such effects.
| Chloramphenicol | May decrease the hematopoietic response to Methylcobalamin. | Moderate |
| Proton Pump Inhibitors (Omeprazole, Pantoprazole) | Long-term use can reduce Vitamin B12 absorption; high-dose Methylcobalamin may overcome this. | Low |
| Metformin | Long-term use can impair B12 absorption; this combination may be compensatory. | Low |
| Colchicine | May reduce absorption of Methylcobalamin. | Moderate |
| Alcohol (Chronic use) | Can worsen neuropathy and increase risk of hepatic effects with Epalrestat. | High |
| Other Hepatotoxic Drugs | Increased risk of liver injury with Epalrestat. | Moderate |
Same composition (Epalrestat (150mg) + Methylcobalamin (1500mcg)), different brands: